FDA Approves Romvimza for Symptomatic Tenosynovial Giant Cell Tumor

The FDA has approved Romvimza, a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity.